Active Filter(s):
Details:
The collaboration aims to develop and commercialize DARPin in the radioligand therapy field. The parties will collaborate in discovery, candidate selection and preclinical development of Athebody® DARPins for use as Radio-DARPin drug entities.
Lead Product(s): DARPin-targeted Radioligand
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Discovery Product Type: Small molecule
Partner/Sponsor/Collaborator: Point Biopharma
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration September 18, 2023